Synchronization of oocyte maturation in vitro has been shown to produce higher in vitro fertilization (IVF) rates than those observed in oocytes matured in vitro without synchronization. However, the increased IVF rates never exceeded those observed in oocytes matured in vivo without synchronization. This study was therefore designed to define the effect of in vivo synchronization of oocyte maturation on IVF rates. Mice were superovulated and orally treated with 7.5 mg cilostazol (CLZ), a phosphodiesterase 3A (PDE3A) inhibitor, to induce ovulation of immature oocytes at different stages depending on frequency and time of administration of CLZ. Mice treated with CLZ ovulated germinal vesicle (GV) or metaphase I (MI) oocytes that underwent maturation in vitro or in vivo (i.e. in the oviduct) followed by IVF. Superovulated control mice ovulated mature oocytes that underwent IVF directly upon collection. Ovulated MI oocytes matured in vitro or in vivo had similar maturation rates but significantly higher IVF rates, 2–4 cell embryos, than those observed in control oocytes. Ovulated GV oocytes matured in vitro showed similar maturation rates but significantly higher IVF rates than those observed in control oocytes. However, ovulated GV oocytes matured in vivo had significantly lower IVF rates than those noted in control oocytes. It is concluded that CLZ is able to synchronize oocyte maturation and improve IVF rates in superovulated mice. CLZ may be capable of showing similar effects in humans, especially since temporal arrest of human oocyte maturation with other PDE3A inhibitors in vitro was found to improve oocyte competence level. The capability of a clinically approved PDE3A inhibitor to improve oocyte fertilization rates in mice at doses extrapolated from human therapeutic doses suggests the potential scenario of the inclusion of CLZ in superovulation programs. This may improve IVF outcomes in infertile patients.
GandolfiTAGandolfiF. The maternal legacy to the embryo: Cytoplasmic components and their effects on early development. Theriogenology2001; 55: 1255–76.
2.
KrisherRL. The effect of oocyte quality on development. J Anim Sci2004; 82: 14–23.
3.
WatsonAJ. Oocyte cytoplasmic maturation: A key mediator of oocyte and embryo developmental competence. J Anim Sci2007; 85: 1–3.
4.
RaghuHMNandiSReddySM. Follicle size and oocyte diameter in relation to developmental competence of buffalo oocytes in vitro. Reprod Fertil Dev2002; 14: 55–61.
5.
OtoiTFujiiMTanakaMOokaASuzukiT. Oocyte diameter in relation to meiotic competence and sperm penetration. Theriogenology2000; 54: 535–42.
6.
ComizzoliPPukazhenthiBSWildtDE. The competence of germinal vesicle oocytes is unrelated to nuclear chromatin configuration and strictly depends on cytoplasmic quantity and quality in the cat model. Hum Reprod2011; 26: 2165–77.
7.
Bouniol BalyCHamraouiLGuibertJBeaujeanNSzöllösiMSDebeyP. Differential transcriptional activity associated with chromatin configuration in fully grown mouse germinal vesicle oocytes. Biol Reprod1999; 60: 580–7.
8.
De La FuenteREppigJ. Transcriptional activity of the mouse oocyte genome: Companion granulosa cells modulate transcription and chromatin remodeling. Dev Biol2001; 229: 224–36.
9.
AlbuzFKSassevilleMLaneMArmstrongDTThompsonJGGilchristRB. Simulated physiological oocyte maturation (SPOM): A novel in vitro maturation system that substantially improves embryo yield and pregnancy outcomes. Hum Reprod2010; 12: 2999–3011.
10.
NogueiraDCortvrindtRDe MatosDGVanhoutteLSmitzJ. Effect of phosphodiesterase type 3 inhibitor on developmental competence of immature mouse oocytes in vitro. Biol Reprod2003; 69: 2045–52.
11.
NogueiraDRon-ElRFriedlerSSchachterMRazielACortvrindtRSmitzJ. Meiotic arrest in vitro by phosphodiesterase 3-inhbitor enhances maturation capacity of human oocytes and allows subsequent embryonic development. Biol Reprod2006; 74: 177–84.
12.
VanhoutteLDe SutterPNogueiraDGerrisJDhontMVan der ElstJ. Nuclear and cytoplasmic maturation of in vitro matured human oocytes after temporary nuclear arrest by phosphodiesterase 3-inhibitor. Hum Reprod2007; 22: 1239–46.
13.
VanhoutteLNogueiraDGerrisJDhontMDe SutterP. Effect of temporary nuclear arrest by phosphodiesterase 3-inhibitor on morphological and functional aspects of in vitro matured mouse Oocytes. Mol Reprod Dev2008; 75: 1021–30.
14.
LiuXMalSMiaoDLiuDBaoSTanJ. Cortical granules behave differently in mouse oocytes matured under different conditions. Hum Reprod2005; 20: 3402–13.
15.
SunQSchattenH. Regulation of dynamic events by microfilaments during oocyte maturation and fertilization. Reproduction2006; 131: 193–205.
16.
VerlhacMHKubiakJZWeberMGeraudGColledgeWHEvansMJMaroB. Mos is required for MAP kinase activation and is involved in microtubule organization during meiotic maturation in the mouse. Development1996; 122: 815–22.
17.
MarangosPCarrollJ. The dynamics of cyclin B1 distribution during meiosis I in mouse oocytes. Reproduction2004; 128: 153–62.
18.
ChoiTAokiFMoriMYamashitaMNagahamaYKohmotoK. Activation of p34cdc2 protein kinase activity in meiotic and mitotic cell cycles in mouse oocytes and embryos. Development1991; 113: 789–95.
19.
LeeSTKimTMChoMYMoonSYHanJYLimJM. Development of a hamster superovulation program and adverse effects of gonadotropins on microfilament formation during oocyte development. Fertil Steril2005; 83: 1264–74.
20.
MaSKalousekDKYuenBHMoonYS. Investigation of effects of pregnant mare serum gonadotropin (PMSG) on the chromosomal complement of CD-1 mouse embryos. J Assist Reprod Genet1997; 14: 162–9.
21.
TaiyebAMRidhaMTSayesCMDeesWLKraemerDC. Cilostazol administered to female mice induces ovulation of immature oocytes: A contraceptive animal model. Life Sci2014; 96: 46–52.
22.
GillJ. Design and analysis of experiments in the animal and medical sciences, Iowa: The Iowa State University Press, 1987.
23.
Van der AuweraID’HoogheT. Superovulation of female mice delays embryonic and fetal development. Hum Reprod2001; 16: 1237–43.
24.
TurRBarriPNCoroleuBBuxaderasRMartínezFBalaschJ. Risk factors for high-order multiple implantation after ovarian stimulation with gonadotrophins: Evidence from a large series of 1878 consecutive pregnancies in a single centre. Hum Reprod2001; 16: 2124–9.
25.
FIVNAT (French In vitro National). Pregnancies and births resulting from in vitro fertilization: French national registry, analysis of data 1986 to 1990. Fertil Steril1995; 64: 746–56.
26.
SundstromIIldgrubenAHogbergU. Treatment-related and treatment-independent deliveries among infertile couples, a long-term follow-up. Acta Obstet Gynecol Scand1997; 76: 238–43.
27.
CurnowECRyanJPSaundersDMHayesES. Oocyte prematuration in the presence of milrinone improves nuclear but not cytoplasmic maturation of macaque oocytes. Reprod Fertil Dev2011; 23: 224–5.
28.
JeeBCChenHYChianRC. Effect of a phosphodiesterase type 3 inhibitor in oocyte maturation medium on subsequent mouse embryo development. Fertil Steril2009; 91: 2037–42.
29.
PatratCKaffelADelarocheLGuibertJJouannetPEpelboinSDe ZieglerDWolfJPFauqueP. Optimal timing for oocyte denudation and intracytoplasmic sperm injection. Obstet Gynecol Int2012; 2012: 1–7.
30.
SundstromPNilssonBO. Meiotic and cytoplasmic maturation of oocytes collected in stimulated cycles is asynchronous. Hum Reprod1988; 3: 613–9.
31.
TrounsonAOMohrLRWoodCLeetonJF. Effect of delayed insemination on in-vitro fertilization, culture and transfer of human embryos. J Reprod Fertil1982; 64: 285–94.
32.
SonWChungJChianRHerreroBDemirtasEElizurSGidoniYSylvestreCDeanNTanSL. A 38 h interval between hCG priming and oocyte retrieval increases in vivo and in vitro oocyte maturation rate in programmed IVM cycles. Hum Reprod2008; 23: 2010–6.
33.
YooHChoHLeeY. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol2010; 69: 27–37.
34.
LiuYShakurYYoshitakeMKambayashi JiJ. Cilostazol (pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev2001; 19: 369–86.
35.
SunBLeSNLinSFongMGuertinMLiuYTandonNNYoshitakeMKambayashiJ. New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol2002; 40: 577–85.
36.
WangSConeJFongMYoshitakeMKambayashiJLiuY. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol2001; 38: 775–83.
37.
WiersmaAHirschBTsafririAHanssenRGJMvan de KantMKloosterboerHJContiMHsuehAJ. Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents. J Clin Invest1998; 102: 532–7.
38.
ThomasREThompsonJGArmstrongDTGilchristRB. Effect of specific phosphodiesterase isoenzyme inhibitors during in vitro maturation of bovine oocytes on meiotic and developmental capacity. Biol Reprod2004; 71: 1142–9.
39.
JensenJSchwinofKZelinski WootenMContiMDePaoloLStoufferR. Phosphodiesterase 3 inhibitors selectively block the spontaneous resumption of meiosis by macaque oocytes in vitro. Hum Reprod2002; 17: 2079–84.
40.
GrupenCFungMArmstrongD. Effects of milrinone and butyrolactone-I on porcine oocyte meiotic progression and developmental competence. Reprod Fertil Dev2006; 18: 309–17.
TaiyebAMDeesWLRidha-AlbarzanchiMTSayesCMKraemerDC. In vitro effects of cilostazol, a phosphodiesterase IIIA inhibitor, on mouse oocyte maturation and morphology. Clin Exp Pharm Physiol2014; 41: 147–53.
